Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Core Viewpoint - Phio Pharmaceuticals is advancing its clinical-stage siRNA gene silencing technology, INTASYL, aimed at treating skin cancer, with a focus on its lead product candidate PH-762, which is currently in a Phase 1b clinical trial [1][4]. Group 1: Company Overview - Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company listed on NASDAQ under the ticker PHIO, specializing in therapeutics that utilize its proprietary INTASYL® siRNA gene silencing technology [1][4]. - The company's lead clinical program, PH-762, targets the PD-1 gene associated with various skin cancers, including cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma [4]. Group 2: Clinical Trial Progress - The ongoing Phase 1b clinical trial for PH-762 is currently treating patients in its fifth cohort, indicating progress towards the anticipated final cohort [1][2]. - The trial is designed to evaluate PH-762 as a potential non-surgical treatment option for skin cancers [4]. Group 3: Upcoming Events - Phio Pharmaceuticals will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8 to 10, 2025, where the CEO will provide updates on the clinical trial and future strategies [1][2][8]. - One-on-one investor meetings will be available during the conference for interested parties [3].